Therapy and Research in Psychedelic Science (TRIPS) Seminar Series

TRIPS is an online seminar series that hosts speakers discussing science-informed presentations and discussions about psychedelics to educate healthcare professionals. This series was created to guide healthcare providers and students preparing to be professionals towards the most relevant, pragmatic, and essential information about psychedelic-assisted therapy, changing legal statuses, and harm reduction approaches in order to better serve clients and communities.

This seminar series is a fundraiser for our clinical trial of MDMA-assisted psychotherapy for social anxiety disorder that Portland Psychotherapy investigators are preparing for and starting in the Fall of 2021. All proceeds after presenter remuneration will go to fund this clinical trial.

These presentations are hosted through Zoom. Each presentation will be approximately 30 minutes with a 30-minute Q&A discussion afterward. Presentations will be recorded and sent to anyone who registers for the event. The recording will be available for 30 days after it has been sent to registered attendees.

Cancellation Policy: We charge a $10 administration fee for cancellations made by participants more than two weeks before the training event. For cancellations within two weeks of the training event, we will refund 50% of the tuition after subtracting the administration fee. Alternately, participants may elect to apply 100% of their tuition to a future TRIPS training event. No refunds will be given after training events.

Cost: $10

Time: Every 2nd Friday of the month from 12:00 PM – 1:00 PM (Pacific Time)

Location: Virtual (through Zoom)


March 12th, 2021 – What does Psilocybin-Assisted Therapy for Depression Look Like? A Clinical Case Presentation based on a Recent Clinical Trial from Johns Hopkins with Alan K. Davis, Ph.D.

This talk will integrate findings from a recent controlled trial of psilocybin therapy for people diagnosed with Major Depressive Disorder with a case report from a patient enrolled in the trial. The efficacy of this intervention will be contextualized within the scope of patient’s experiences and a description of the therapeutic process involved in preparing for and integrating psilocybin experiences as part of therapy.

April 9th, 2021 – Ketamine 101: An Introduction to Ketamine-Assisted Psychotherapy with Gregory Wells, Ph.D.

Ketamine-assisted psychotherapy (KAP) has recently emerged as one of the most innovative treatments for depression (particularly treatment-resistant depression (TRD), anxiety, post-traumatic stress disorder (PTSD) as well as a host of other psychological conditions. Integrating pharmacological, psychological, and archetypal/transpersonal elements, KAP represents a new synthesis (or hybrid model) of psychotherapy. Empirical results, particularly during the past decade, demonstrate that ketamine and KAP may be able to assist clinical populations whose symptoms and psychological issues have not been responsive to treatment by other means. At the same time, KAP holds promise for effective treatment of individuals with end-of-life anxiety, existential distress, and less severe diagnoses. The practice of KAP, including diverse dosing strategies, allows clinicians to craft intervention strategies at both the psycholytic (trance, self-reflective) and psychedelic (transformational/transpersonal) levels of experience. This short introductory course will cover a wide range of topics to help clinicians understand the potential use and efficacy of KAP, as well as other psychedelic medicines, and will present the current state of the art clinical models for these treatments. Recent promising lines of research in the field will also be briefly covered.

May 14th, 2021 Research on MDMA and Psychedelic-Assisted Therapy: An Overview of the Evidence for Clinicians with Jason Luoma, Ph.D.

This presentation is for those who want to understand the breadth of the existing research on the effectiveness of psychedelic and MDMA-assisted therapy. We will review all existing placebo-controlled randomized trials, as well as open trials. Much of this presentation is based on a recent meta-analysis that this presenter published. Attendees will walk away with a broad understanding of the strength and breadth of the existing data on psychedelic assisted therapy and how it compares to other treatments.

June 11th, 2021 – Becoming a Psychedelic-Informed Therapist: Toward Developing Your Own Practice with Nathan Gates, M.A.

Psychedelic medicine seems poised at the cusp of a major boom, potentially evoking major changes in the way psychological suffering is treated. Established and developing professionals alike may find themselves wondering how psychedelic-assisted therapy might affect their practice, and how they could get involved. There are a number of ways in which psychedelic-assisted psychotherapy differs significantly from most models of practice that clinicians have been trained in over the last few decades. These differences may force our field to revisit numerous habits and patterns of behavior that have both consciously and unconsciously shaped the current practice of therapy. At the moment, while best practices are still very much in question, there remain far more questions than answers. For those eager to integrate psychedelic medicines into their work, becoming a psychedelic-assisted psychotherapist may still seem more aspirational than realistic. In this seminar, we will discuss some of the ways in which psychedelic-assisted psychotherapy may overlap with skills and stances we already hold. Additionally, psychedelic practice may require us to adjust our skill sets, clarify our ideas about our role in facilitating therapeutic change, and perhaps even adapt our worldview. Allowing psychedelic experiencing to inform our approach as therapists is a reasonable first step towards integrating them into our practices. In this way, becoming a psychedelic-informed therapist may be a crucial first step towards becoming a psychedelic-assisted psychotherapist.

More Dates To Be Announced
Please check back in or sign up for our newsletter to check out additional presentations added.


December 11th, 2020 – Ethical and Legal Considerations in Providing Psychedelic Integration Therapy with Brian Pilecki, Ph.D. & Jason Luoma, Ph.D.

There is an increasing demand from clients seeking therapeutic support in their use of psychedelics as tools for personal growth and healing. However, many clinicians interested in psychedelic preparation and integration are unsure as to how to provide these services while psychedelics remain illegal. This webinar will outline legal and ethical frameworks relevant to providing therapy to clients around their use of psychedelics, as well as describe how harm reduction approaches are suitable for this new clinical area. We will outline the most common ethical and legal risks for therapists engaging in this work and steps to mitigate this risk. We also discuss common decision points and provide reflection questions for clinicians considering involvement in psychedelic integration therapy.

January 8th, 2021 – What’s it Like to Trip? The Patient Experience in Psychedelic-Assisted Therapy with Brian Pilecki, Ph.D.

There has been a resurgence of interest in the use of psychedelic substances to treat mental health problems, largely due to strong outcome data of recent clinical trials investigating psychedelic assisted therapy. While many are familiar with this research, there seems to be less clarity around what the patient experience is like. How does psychedelic-assisted therapy work? How do psychedelic experiences lead to positive change or improvement? This webinar will outline the patient experience in this new form of treatment, including what is like to attend preparation sessions, dosing sessions, and follow-up integration sessions with therapists. Experiences from patients who participated in clinical trials will be included to help illustrate how psychedelics helped them.

February 12th, 2021 – Returning From All: Integrating 5-MeO-DMT Experiences in Psychotherapy with Rafael Lancelotta, M.S.

While there has been positive press about the potential benefits of 5-MeO-DMT use in the general population, there have been many cases in which people have not been adequately prepared, used too much, or did not have adequate support following their experience. In this presentation, Rafael will talk about protective measures that have been studied in his research and discuss how therapists might approach supporting clients after an experience that has left them dysregulated and overwhelmed.

If you would like to stay up to date on information about the TRIPS seminar series, you can join our newsletter by clicking on the button above.